Advanced Malignancies
Showing NaN - NaN of 10
Advanced Malignancies, NSCLC, Ovarian Cancer Trial in Worldwide (Avelumab, Lorlatanib, Talazoparib)
Recruiting
- Advanced Malignancies
- +4 more
- Avelumab
- +7 more
-
Fayetteville, Arkansas
- +61 more
Jan 10, 2023
Advanced Malignancies, Metastatic Cancer Trial in Worldwide (INCAGN01876, Nivolumab, Ipilimumab)
Completed
- Advanced Malignancies
- Metastatic Cancer
- INCAGN01876
- +2 more
-
Los Angeles, California
- +37 more
Dec 6, 2022
Recurrent Cancer, Metastatic Cancer, Advanced Malignancies Trial (INCAGN01876, retifanlimab)
Recruiting
- Recurrent Cancer
- +3 more
- INCAGN01876
- retifanlimab
-
Birmingham, Alabama
- +17 more
Dec 13, 2022
Advanced Malignancies, Metastatic Cancer Trial in United States (INCAGN01876)
Completed
- Advanced Malignancies
- Metastatic Cancer
-
Los Angeles, California
- +7 more
Feb 9, 2021
Advanced Malignancies, Metastatic Cancer Trial in Worldwide (INCAGN01949)
Completed
- Advanced Malignancies
- Metastatic Cancer
-
New Brunswick, New Jersey
- +7 more
May 6, 2020
Solid Tumors, Advanced Malignancies, Metastatic Cancer Trial in United States (INCB052793, gemcitabine, nab-paclitaxel)
Advanced Cancer, Advanced Malignancies Trial in Australia, Spain, United States (Cemiplimab, Hypofractionated radiotherapy,
Completed
- Advanced Cancer
- Advanced Malignancies
- Cemiplimab
- +7 more
-
Gilbert, Arizona
- +46 more
Jan 23, 2020
Advanced Malignancies Trial in United States (CDX-1401 in combination with Resiquimod and/or Poly-ICLC, CDX-1401, Resiquimod)
Completed
- Advanced Malignancies
- CDX-1401 in combination with Resiquimod and/or Poly-ICLC
- +3 more
-
New Haven, Connecticut
- +6 more
Jun 22, 2016